Glembatumumab vedotin for patients with metastatic, gpNMB overexpressing, triple-negative breast cancer (“METRIC”): a randomized multicenter study

Abstract The METRIC study (NCT#0199733) explored a novel antibody–drug conjugate, glembatumumab vedotin (GV), targeting gpNMB that is overexpressed in ~40% of patients with triple-negative breast cancer (TNBC) and associated with poor prognosis. The study was a randomized, open-label, phase 2b study...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Linda T. Vahdat, Peter Schmid, Andres Forero-Torres, Kimberly Blackwell, Melinda L. Telli, Michelle Melisko, Volker Möbus, Javier Cortes, Alberto J. Montero, Cynthia Ma, Rita Nanda, Gail S. Wright, Yi He, Thomas Hawthorne, Rebecca G. Bagley, Abdel-Baset Halim, Christopher D. Turner, Denise A. Yardley
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/17180d15d53a444b97cb83ce78fb7480
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:17180d15d53a444b97cb83ce78fb7480
record_format	dspace
spelling	oai:doaj.org-article:17180d15d53a444b97cb83ce78fb74802021-12-02T17:18:05ZGlembatumumab vedotin for patients with metastatic, gpNMB overexpressing, triple-negative breast cancer (“METRIC”): a randomized multicenter study10.1038/s41523-021-00244-62374-4677https://doaj.org/article/17180d15d53a444b97cb83ce78fb74802021-05-01T00:00:00Zhttps://doi.org/10.1038/s41523-021-00244-6https://doaj.org/toc/2374-4677Abstract The METRIC study (NCT#0199733) explored a novel antibody–drug conjugate, glembatumumab vedotin (GV), targeting gpNMB that is overexpressed in ~40% of patients with triple-negative breast cancer (TNBC) and associated with poor prognosis. The study was a randomized, open-label, phase 2b study that evaluated progression-free survival (PFS) of GV compared with capecitabine in gpNMB-overexpressing TNBC. Patients who had previously received anthracycline and taxane-based therapy were randomized 2:1 to receive, GV (1.88 mg/kg IV q21 days) or capecitabine (2500 mg/m2 PO daily d1–14 q21 days). The primary endpoint was RECIST 1.1 PFS per independent, blinded central review. In all, 327 patients were randomized to GV (213 treated) or capecitabine (92 treated). Median PFS was 2.9 months for GV vs. 2.8 months for capecitabine. The most common grade ≥3 toxicities for GV were neutropenia, rash, and leukopenia, and for capecitabine were fatigue, diarrhea, and palmar-plantar erythrodysesthesia. The study did not meet the primary endpoint of improved PFS over capecitabine or demonstrate a relative risk/benefit improvement over capecitabine.Linda T. VahdatPeter SchmidAndres Forero-TorresKimberly BlackwellMelinda L. TelliMichelle MeliskoVolker MöbusJavier CortesAlberto J. MonteroCynthia MaRita NandaGail S. WrightYi HeThomas HawthorneRebecca G. BagleyAbdel-Baset HalimChristopher D. TurnerDenise A. YardleyNature PortfolioarticleNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENnpj Breast Cancer, Vol 7, Iss 1, Pp 1-10 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Linda T. Vahdat Peter Schmid Andres Forero-Torres Kimberly Blackwell Melinda L. Telli Michelle Melisko Volker Möbus Javier Cortes Alberto J. Montero Cynthia Ma Rita Nanda Gail S. Wright Yi He Thomas Hawthorne Rebecca G. Bagley Abdel-Baset Halim Christopher D. Turner Denise A. Yardley Glembatumumab vedotin for patients with metastatic, gpNMB overexpressing, triple-negative breast cancer (“METRIC”): a randomized multicenter study
description	Abstract The METRIC study (NCT#0199733) explored a novel antibody–drug conjugate, glembatumumab vedotin (GV), targeting gpNMB that is overexpressed in ~40% of patients with triple-negative breast cancer (TNBC) and associated with poor prognosis. The study was a randomized, open-label, phase 2b study that evaluated progression-free survival (PFS) of GV compared with capecitabine in gpNMB-overexpressing TNBC. Patients who had previously received anthracycline and taxane-based therapy were randomized 2:1 to receive, GV (1.88 mg/kg IV q21 days) or capecitabine (2500 mg/m2 PO daily d1–14 q21 days). The primary endpoint was RECIST 1.1 PFS per independent, blinded central review. In all, 327 patients were randomized to GV (213 treated) or capecitabine (92 treated). Median PFS was 2.9 months for GV vs. 2.8 months for capecitabine. The most common grade ≥3 toxicities for GV were neutropenia, rash, and leukopenia, and for capecitabine were fatigue, diarrhea, and palmar-plantar erythrodysesthesia. The study did not meet the primary endpoint of improved PFS over capecitabine or demonstrate a relative risk/benefit improvement over capecitabine.
format	article
author	Linda T. Vahdat Peter Schmid Andres Forero-Torres Kimberly Blackwell Melinda L. Telli Michelle Melisko Volker Möbus Javier Cortes Alberto J. Montero Cynthia Ma Rita Nanda Gail S. Wright Yi He Thomas Hawthorne Rebecca G. Bagley Abdel-Baset Halim Christopher D. Turner Denise A. Yardley
author_facet	Linda T. Vahdat Peter Schmid Andres Forero-Torres Kimberly Blackwell Melinda L. Telli Michelle Melisko Volker Möbus Javier Cortes Alberto J. Montero Cynthia Ma Rita Nanda Gail S. Wright Yi He Thomas Hawthorne Rebecca G. Bagley Abdel-Baset Halim Christopher D. Turner Denise A. Yardley
author_sort	Linda T. Vahdat
title	Glembatumumab vedotin for patients with metastatic, gpNMB overexpressing, triple-negative breast cancer (“METRIC”): a randomized multicenter study
title_short	Glembatumumab vedotin for patients with metastatic, gpNMB overexpressing, triple-negative breast cancer (“METRIC”): a randomized multicenter study
title_full	Glembatumumab vedotin for patients with metastatic, gpNMB overexpressing, triple-negative breast cancer (“METRIC”): a randomized multicenter study
title_fullStr	Glembatumumab vedotin for patients with metastatic, gpNMB overexpressing, triple-negative breast cancer (“METRIC”): a randomized multicenter study
title_full_unstemmed	Glembatumumab vedotin for patients with metastatic, gpNMB overexpressing, triple-negative breast cancer (“METRIC”): a randomized multicenter study
title_sort	glembatumumab vedotin for patients with metastatic, gpnmb overexpressing, triple-negative breast cancer (“metric”): a randomized multicenter study
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/17180d15d53a444b97cb83ce78fb7480
work_keys_str_mv	AT lindatvahdat glembatumumabvedotinforpatientswithmetastaticgpnmboverexpressingtriplenegativebreastcancermetricarandomizedmulticenterstudy AT peterschmid glembatumumabvedotinforpatientswithmetastaticgpnmboverexpressingtriplenegativebreastcancermetricarandomizedmulticenterstudy AT andresforerotorres glembatumumabvedotinforpatientswithmetastaticgpnmboverexpressingtriplenegativebreastcancermetricarandomizedmulticenterstudy AT kimberlyblackwell glembatumumabvedotinforpatientswithmetastaticgpnmboverexpressingtriplenegativebreastcancermetricarandomizedmulticenterstudy AT melindaltelli glembatumumabvedotinforpatientswithmetastaticgpnmboverexpressingtriplenegativebreastcancermetricarandomizedmulticenterstudy AT michellemelisko glembatumumabvedotinforpatientswithmetastaticgpnmboverexpressingtriplenegativebreastcancermetricarandomizedmulticenterstudy AT volkermobus glembatumumabvedotinforpatientswithmetastaticgpnmboverexpressingtriplenegativebreastcancermetricarandomizedmulticenterstudy AT javiercortes glembatumumabvedotinforpatientswithmetastaticgpnmboverexpressingtriplenegativebreastcancermetricarandomizedmulticenterstudy AT albertojmontero glembatumumabvedotinforpatientswithmetastaticgpnmboverexpressingtriplenegativebreastcancermetricarandomizedmulticenterstudy AT cynthiama glembatumumabvedotinforpatientswithmetastaticgpnmboverexpressingtriplenegativebreastcancermetricarandomizedmulticenterstudy AT ritananda glembatumumabvedotinforpatientswithmetastaticgpnmboverexpressingtriplenegativebreastcancermetricarandomizedmulticenterstudy AT gailswright glembatumumabvedotinforpatientswithmetastaticgpnmboverexpressingtriplenegativebreastcancermetricarandomizedmulticenterstudy AT yihe glembatumumabvedotinforpatientswithmetastaticgpnmboverexpressingtriplenegativebreastcancermetricarandomizedmulticenterstudy AT thomashawthorne glembatumumabvedotinforpatientswithmetastaticgpnmboverexpressingtriplenegativebreastcancermetricarandomizedmulticenterstudy AT rebeccagbagley glembatumumabvedotinforpatientswithmetastaticgpnmboverexpressingtriplenegativebreastcancermetricarandomizedmulticenterstudy AT abdelbasethalim glembatumumabvedotinforpatientswithmetastaticgpnmboverexpressingtriplenegativebreastcancermetricarandomizedmulticenterstudy AT christopherdturner glembatumumabvedotinforpatientswithmetastaticgpnmboverexpressingtriplenegativebreastcancermetricarandomizedmulticenterstudy AT deniseayardley glembatumumabvedotinforpatientswithmetastaticgpnmboverexpressingtriplenegativebreastcancermetricarandomizedmulticenterstudy
_version_	1718381129783836672

Glembatumumab vedotin for patients with metastatic, gpNMB overexpressing, triple-negative breast cancer (“METRIC”): a randomized multicenter study

Ejemplares similares